Generic Name and Formulations:
Pentoxifylline 400mg; ext-rel tabs.
Indications for TRENTAL:
400mg three times daily with meals. Continue for at least 8 weeks. Digestive or CNS effects: lower dosage to 400mg twice daily; discontinue if side effects persist. Severe renal impairment (CrCl <30mL/min): 400mg once daily.
Recent cerebral or retinal hemorrhage. Methylxanthines intolerance (eg, caffeine, theophylline, theobromine).
Discontinue if anaphylactic/anaphylactoid reaction occurs. Monitor for bleeding including hematocrit, hemoglobin in patients with hemorrhagic risk factors (eg, recent surgery, peptic ulcer, cerebral and/or retinal bleeding). Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hemorrheologic agent (xanthine).
See Contraindications. May potentiate antihypertensives; monitor BP. Concomitant theophylline-containing drugs; monitor closely and adjust dose. Bleeding with concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. Concomitant warfarin; monitor PT frequently. May be potentiated by strong CYP1A2 inhibitors (eg, ciprofloxacin, fluvoxamine), cimetidine.
GI upset, nausea, dyspepsia, flushing, agitation, headache, dizziness, insomnia, blurred vision.
Renal (primarily), fecal.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally